Table 1.
Baseline Patient, Tumor and Treatment Characteristics for All Patients (n = 115).
| Characteristic | n (%) or median (IQR) |
|---|---|
| Age at diagnosis (years) | 71 (64-78) |
| Sex | |
| Male | 73 (63.5%) |
| Female | 42 (36.5%) |
| ECOG performance status | |
| 0-1 | 80 (69.6%) |
| 2 | 35 (30.4%) |
| Smoking status | |
| Positive | 51 (44.3%) |
| Negative | 57 (49.6%) |
| Unknown | 7 (6.1%) |
| Underlying respiratory system disease | |
| Yes | 63 (54.8%) |
| No | 52 (45.2%) |
| Tumor diameter (mm) | 20.20 (15.45-30.00) |
| Tumor location | |
| Central | 33 (28.7%) |
| Peripheral | 82 (71.3%) |
| SUVmax | 6.00 (2.35-12.30) |
| Histology | |
| Adenocarcinoma | 69 (60.00%) |
| Squamous carcinoma | 22 (19.1%) |
| Unknown | 24 (20.9%) |
| Tumor volume (cm3) | |
| GTV | 9.71 (3.99-23.11) |
| PTV | 23.66 (11.92-48.62) |
| SBRT dose and fractionation | |
| 50 Gy in 5 fractions | 38 (33.0%) |
| 60 Gy in 10 fractions | 77 (67.0%) |
| Radiation time (seconds) | 3599 (2857-4876) |
| Key mean normal tissue doses (cGy) | |
| mean lung dose | 427.00 (313.00-600.00) |
| mean heart dose | 120.50 (23.25-409.75) |
| Radiation-induced lymphopenia | 63 (54.78%) |
| Lymphocytes recover to pre-SBRT level | 44 (38.26%) |
Abbreviations: IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group; GTV, gross tumor volume; PTV, planning target volume; SBRT, stereotactic body radiation therapy.